Table 3.
Secondary Outcomes
| Outcome | iNO (N=98) | iEPO (N=103) | Risk Difference, % (95% CI) | aRelative Risk (95% CI) | P-value |
|---|---|---|---|---|---|
| Mortality | |||||
| 30-Day | 2 (2.0%) | 1 (1.0%) | −1.0 (−4.0, 2.0) | 2.10 (0.19, 22.81) | 0.61 |
| 90-Day | 4 (4.1%) | 4 (3.9%) | 0.2 (−6.0, 5.0) | 1.05 (0.27, 4.09) | 0.94 |
| In-Hospital | 5 (5.1%) | 7 (6.8%) | 1.7 (−5.0, 8.0) | 0.75 (0.25, 2.29) | 0.61 |
| Tracheostomy | 22 (22.4%) | 29 (28.2%) | 5.8 (−6.0 to 18.0) | 0.80 (0.49, 1.29) | 0.35 |
| bAKI of any stage | 72 (73.5%) | 67 (65.0%) | −8.5 (−20.0, 5.0) | 1.12 (0.93, 1.34) | 0.23 |
| bAKI stages 2 or 3 | 29 (29.6%) | 24 (23.3%) | −6.3 (−18.0, 6.0) | 1.26 (0.79, 2.00) | 0.33 |
| d HL Location Shift (95% CI) | e Mean Ratio (95% CI) | ||||
| ICU LOS (days) | 4 (2, 10) | 4 (2, 10) | 0 (−1, 1) | 1.19 (0.76, 1.87) | 0.45 |
| Hospital LOS (days) | 23 (16, 38) | 23 (15, 38) | 0 (−3, 3) | 1.03 (0.75, 1.41) | 0.86 |
| Duration of mechanical ventilation (hours) | |||||
| fKM Median (95% CI) Estimates | 19 (15, 24) | 22 (17, 36) | 0.75g | ||
Relative Risk (with p-values) of developing the outcome if participants receive iNO rather than iEPO.
Kidney Disease-Improving Global Outcomes AKI grading include stages 1, 2 or 3 in ascending order of severity. AKI stage 2 and 3 are more commonly associated with poor outcomes after Lung Transplantation (LT) and AKI incidence is independent of PGD-3 occurrence.40
Hodges-Lehmann non-normal difference estimator
Mean ratio with P-values from log-linear models.
Measured from 197 patients (four patients had pre-LT tracheostomy). For those that received postoperative tracheostomy, time-to-extubation interval was censored at the time of tracheostomy placement to avoid underestimating the distribution of time-to-end of mechanical ventilation.
Log-rank P-value
AKI, Acute kidney injury; ICU, Intensive care unit; KM, Kaplan-Meier analysis; LOS, Length-of-stay.